Research

With one of the largest and most productive vascular surgery research programs in the country, Michigan surgeons and investigators develop knowledge that advances our understanding of disease mechanisms, and produces new treatments and techniques to improve patients’ lives.

With 3 full-time research faculty, as well as clinical faculty who perform research, Michigan Vascular Surgery investigators publish as many as 100 publications a year, covering the spectrum of basic science, translational, clinical, and health services research.

Our efforts are supported by over $2.5 million in funding, including through an NIH T32 Training Grant that kickstarts the careers of postdoctoral fellows pursuing breakthroughs in vascular biology.

The hub for our research efforts is the Conrad Jobst Vascular Research Laboratories, located in U-M’s North Campus Research Complex, a 28-building campus designed for teamwork across the disciplines. By uniting the section’s research efforts in the Jobst, we’re able to accelerate discovery through sharing ideas and resources, including core unit support for molecular, hematology and cell biology.

This highly collaborative approach reflects our culture and our passion for teaching at the bench. We’ve welcomed everyone from high schoolers to international visiting scholars to our labs.

Current research interests include:

  • Arrhythmia: In partnership with U-M’s Center for Arrhythmia Research, we’re pursuing new technology that facilitates the mapping of complex arrhythmias, particularly atrial fibrillation. This effort aims to advance our understanding of and treatments for the most challenging and prevalent heart rhythm disorders.
  • Venous thrombosis: We’re developing a new approach to treating venous thrombosis by finding ways to limit the body’s inflammatory response without increasing the potential for bleeding. This novel anticoagulate, an E-selectin inhibitor, is the subject of a current clinical trial — just one example of how our research informs our clinical practice.
  • Device development and trials: For more than a decade, we’ve worked to continuously improve aortic devices to boost the safety and effectiveness of minimally invasive aneurysm repair. Our work in device development in the areas of vascular injury and hemorrhage control has resulted in FDA-approved devices now used throughout the U.S. Through collaborations between biomedical engineers, clinicians, and basic science researchers, we’re also improving the process for developing devices, combining high-tech approaches with clinical expertise.